Netakimab (BCD-085): A Comprehensive Clinical and Scientific Monograph

Executive Summary

Netakimab, developed by the Russian biotechnology firm Biocad and marketed under the brand name Efleira®, is a novel, humanized monoclonal antibody representing a significant advancement in the class of interleukin-17 (IL-17) inhibitors. Its unique molecular architecture, derived from llama immunoglobulins, features a highly specific, high-affinity binding domain that targets the pro-inflammatory cytokine IL-17A, a key driver in the pathophysiology of several autoimmune diseases. Some evidence also indicates binding to IL-17F, positioning it mechanistically alongside next-generation dual inhibitors.

The clinical development program for Netakimab has robustly demonstrated its efficacy and safety across its core indications. The pivotal Phase 3 trials—PLANETA in moderate-to-severe plaque psoriasis, PATERA in active psoriatic arthritis, and ASTERA in active ankylosing spondylitis—have consistently shown statistically significant and clinically meaningful superiority over placebo. Key findings across these studies include a rapid onset of action, with symptomatic improvement observed within weeks, and high rates of clinical response in both biologic-naïve and treatment-experienced patient populations. The efficacy is durable, with clinical benefits maintained in long-term extension studies of up to three years.

The safety profile of Netakimab is favorable and consistent with the established profile of the IL-17 inhibitor class. The most common adverse events include upper respiratory tract infections and manageable laboratory abnormalities such as neutropenia and elevated liver enzymes. A notable feature of Netakimab is its low immunogenicity, a characteristic likely attributable to its unique molecular design, which may translate to enhanced long-term drug survival and sustained efficacy.

Netakimab is currently approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in Russia and Belarus. Its commercialization follows a non-traditional "East-first" strategy, with advanced-stage clinical development ongoing in China and for pediatric populations. While plans for European Union registration have been announced, its entry into the highly competitive Western markets remains a future objective that will likely require head-to-head comparator trials. Overall, Netakimab stands as a potent and effective therapeutic agent and a notable example of biopharmaceutical innovation emerging from outside the traditional US/EU development ecosystem.

Molecular Profile and Mechanism of Action

Drug Identification and Classification

Netakimab is a biologic therapeutic agent identified by the International Nonproprietary Name (INN) Netakimab. During its development by the Russian biotechnology company Biocad CJSC, it was designated by the code BCD-085.[1] Upon marketing approval, it was assigned the brand name Efleira®.[1]

Pharmacologically, Netakimab is classified as a monoclonal antibody and, more specifically, as an interleukin inhibitor belonging to the Anatomical Therapeutic Chemical (ATC) code L04AC.[2] Its mechanism of action places it in the therapeutic class of Interleukin-17A (IL-17A) inhibitors.[1] As a novel therapeutic, it is recognized as a New Molecular Entity.[1] The development of Netakimab was originated and primarily conducted by Biocad, with strategic partnerships, including SPH-BIOCAD and Shangyao Bokang Biomedical, established for its clinical development and potential commercialization in China.[1]

Unique Molecular Structure: A Llama-Derived Foundation

The molecular structure of Netakimab is a key differentiator from other monoclonal antibodies in its class. It is a recombinant, humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody with a novel foundation derived from the immunoglobulins of the llama (Lama glama).[4] Llama immunoglobulins possess a unique structural feature: a subset of functional antibodies that are devoid of light chains and are composed solely of two heavy chains.[4]

Biocad employed a proprietary "smart humanization" process to engineer Netakimab. In this process, the variable domain of the human heavy chain (VH) was replaced with a llama-derived variable domain of a heavy-chain-only antibody, known as a VHH domain or Nanobody®.[5] A critical feature of this VHH domain is a long complementarity-determining region 3 (CDR-H3), which forms an extended loop that can access epitopes unavailable to conventional antibodies, contributing to its high specificity and affinity.[5]

To minimize immunogenicity, the remainder of the antibody scaffold was extensively humanized. The llama-derived amino acid sequences were meticulously restricted to only the CDRs, the specific regions responsible for antigen binding. The framework regions of the heavy chain and a modified IgG1 Fc-fragment were replaced with human sequences, and fully human light chains (of the VK3 structural family) were incorporated to complete the conventional antibody structure.[4] This sophisticated bioengineering approach is designed to yield a molecule that retains the superior binding characteristics of the llama VHH domain while appearing largely human to the patient's immune system, thereby maximizing affinity and minimizing the potential for generating anti-drug antibodies.[4]

Pharmacodynamics: Targeted Neutralization of the IL-17A Pathway

The therapeutic effect of Netakimab is achieved through the targeted inhibition of the IL-23/IL-17 inflammatory axis, which is now understood to be a central pathway in the pathogenesis of several autoimmune and inflammatory diseases.[9] The primary molecular target of Netakimab is Interleukin-17A (IL-17A), a potent, pro-inflammatory cytokine.[3] Some developer-provided information also indicates that Netakimab binds to Interleukin-17F (IL-17F), a related cytokine with partially overlapping functions.[4]

IL-17A is the signature cytokine produced by T helper 17 (Th17) cells, as well as by other immune cells of both the innate and adaptive systems.[9] In diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis, IL-17A is found in high concentrations in affected tissues, including psoriatic plaques and synovial fluid.[8] It exerts its effects by binding to a receptor complex (composed of IL-17RA and IL-17RC subunits) present on a wide variety of cells, including keratinocytes in the skin, fibroblasts, and synovial cells in the joints.[9] This binding triggers a downstream signaling cascade that results in the production and release of numerous other inflammatory mediators, such as IL-6, chemokines (e.g., CXCL1, CCL20), and matrix metalloproteinases.[10] This cascade amplifies the inflammatory response, leading to the robust recruitment of neutrophils and other immune cells to the site of inflammation, which perpetuates tissue damage, bone resorption, and the clinical signs and symptoms of the disease.[8]

Netakimab functions by binding with high affinity and specificity directly to the IL-17A cytokine, effectively neutralizing it.[10] This action physically prevents IL-17A from docking with its cell-surface receptors, thereby blocking the initiation of the downstream inflammatory cascade.[11] By interrupting this crucial step, Netakimab dampens the inflammatory process, leading to a reduction in tissue inflammation, alleviation of symptoms, and improvement in disease activity scores.[10] The potential for dual neutralization of both IL-17A and IL-17F is significant, as IL-17F also contributes to the inflammatory milieu, particularly in psoriatic skin.[13] While IL-17F is generally less potent than IL-17A, its high concentration in certain tissues means that its inhibition could contribute to a more profound and complete suppression of the IL-17 pathway, a mechanism leveraged by newer-generation IL-17 inhibitors.[15]

Parameter	Description
Generic Name	Netakimab
Brand Name	Efleira® 1
Development Code	BCD-085 1
Drug Class	Monoclonal Antibody, Interleukin-17A Inhibitor 1
Molecular Target	Interleukin-17A (IL-17A); also reported to bind Interleukin-17F (IL-17F) 3
Mechanism of Action	Binds to and neutralizes IL-17A, preventing its interaction with the IL-17 receptor and inhibiting the downstream inflammatory cascade.10
Molecular Structure	Humanized IgG1/kappa monoclonal antibody featuring a llama-derived VHH domain in place of the human VH domain.4
Originator/Developer	Biocad CJSC (Russia).1

Clinical Development and Efficacy in Approved Indications

The clinical development program for Netakimab has been comprehensive, focusing on three core rheumatological and dermatological indications. The efficacy and safety have been established through three pivotal, international, multicenter, randomized, placebo-controlled Phase 3 trials: PLANETA for plaque psoriasis, PATERA for psoriatic arthritis, and ASTERA for ankylosing spondylitis.

Trial Name (Identifier)	Indication	Phase	N (Patients)	Design	Primary Endpoint
PLANETA (NCT03390101)	Moderate-to-Severe Plaque Psoriasis	3	213	Randomized, Double-Blind, Placebo-Controlled	Proportion of patients achieving PASI 75 at Week 12.7
PATERA (NCT03598751)	Active Psoriatic Arthritis	3	194	Randomized, Double-Blind, Placebo-Controlled	Proportion of patients achieving ACR20 at Week 24.17
ASTERA (NCT03447704)	Active Ankylosing Spondylitis	3	228	Randomized, Double-Blind, Placebo-Controlled	Proportion of patients achieving ASAS40 at Week 16.19

Plaque Psoriasis (The PLANETA Program)

The PLANETA study (NCT03390101) was the pivotal Phase 3 trial that evaluated Netakimab for the treatment of moderate-to-severe plaque psoriasis.[7] Conducted across 24 sites in Russia and Belarus, the trial enrolled 213 adult patients with a diagnosis of at least 6 months, a Psoriasis Area and Severity Index (PASI) score of 12 or higher, and body surface area (BSA) involvement of 10% or more, who were candidates for systemic therapy or phototherapy.[5]

Patients were randomized in a 2:2:1 ratio to one of three arms: Netakimab 120 mg administered subcutaneously every 2 weeks (Q2W), Netakimab 120 mg every 4 weeks (Q4W), or placebo.[16] Both active treatment arms included a weekly induction phase for the first three weeks (Weeks 0, 1, and 2).[16] The initial treatment period was a 12-week double-blind, placebo-controlled phase, followed by an open-label extension phase where patients continued treatment for up to three years.[7]

The efficacy results from PLANETA were robust and demonstrated a profound clinical benefit. The study successfully met its primary endpoint, the proportion of patients achieving a 75% reduction from baseline in PASI score (PASI 75) at Week 12.[16] In the intent-to-treat (ITT) population, 83.3% of patients in the Q4W dosing group and 77.7% in the Q2W group achieved PASI 75, compared with 0% of patients in the placebo group (

p<0.0001 for both comparisons).[7] This high level of efficacy was consistent with other key secondary endpoints, including the proportion of patients achieving clear or almost clear skin, defined as a static Physician's Global Assessment (sPGA) score of 0 or 1. At Week 12, approximately 80% of patients in the active treatment arms reached this endpoint.[21] Importantly, the therapeutic effect was not only potent but also durable, as the high rates of clinical response were maintained throughout the first year of treatment, indicating a sustained benefit for patients with this chronic condition.[7]

Psoriatic Arthritis (The PATERA Program)

The efficacy of Netakimab in active psoriatic arthritis (PsA) was established in the PATERA study (NCT03598751).[17] This Phase 3, international, randomized, double-blind, placebo-controlled trial included 194 adult patients with a confirmed diagnosis of PsA who had exhibited an inadequate response or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) or one tumor necrosis factor inhibitor (TNFi).[17]

Participants were randomized 1:1 to receive either Netakimab 120 mg or placebo, administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, and 22.[8] The study design included a rescue provision: patients in the placebo arm who did not achieve at least a 20% improvement according to the American College of Rheumatology criteria (ACR20) by Week 16 were switched to active Netakimab therapy in a blinded fashion.[17]

The PATERA study met its primary endpoint with overwhelming statistical significance. At Week 24, 82.5% of patients treated with Netakimab achieved an ACR20 response, a stark contrast to the 9.3% response rate observed in the placebo group (p<0.0001).[17] The treatment effect was not limited to this primary measure. Netakimab also demonstrated superiority in achieving higher bars of clinical response, with significantly greater proportions of patients attaining ACR50 (70.1% vs. 6.2%) and ACR70 (45.4% vs. 3.1%) responses compared to placebo.[17]

The robust efficacy was further confirmed across a range of PsA-specific composite indices. Significant improvements versus placebo were observed for the Psoriatic Arthritis Response Criteria (PsARC; 86.6% vs. 28.9%), achievement of Minimal Disease Activity (MDA; 42.3% vs. 1.0%), and remission as measured by the Disease Activity Index for Psoriatic Arthritis (DAPSA; 36.1% vs. 13.4%).[17] The benefits of Netakimab extended to all key domains of this heterogeneous disease. Sub-analyses confirmed that Netakimab was effective in patients with axial involvement (inflammatory back pain) [23] and also led to significant improvements in skin manifestations (PASI75/90/100), nail psoriasis (as measured by NAPSI), and enthesitis (as measured by the Leeds Enthesitis Index).[24] Long-term data from the 3-year extension of the PATERA study showed that the therapeutic response achieved in the first year was maintained throughout the extended follow-up period, demonstrating durable control of PsA manifestations.[25]

Ankylosing Spondylitis (The ASTERA Program)

The ASTERA study (NCT03447704) was the pivotal Phase 3 trial that assessed Netakimab in patients with active ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the axial skeleton.[19] This double-blind, multicenter, randomized, placebo-controlled trial enrolled 228 adult patients with active AS, defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 4 or greater, who had persistent disease activity despite treatment with non-steroidal anti-inflammatory drugs (NSAIDs).[19]

Patients were randomized 1:1 to receive either Netakimab 120 mg or placebo via subcutaneous injection.[19] The dosing schedule involved an induction phase with injections at Weeks 0, 1, and 2, followed by maintenance dosing every two weeks until Week 14.[19] After the 16-week blinded period, all patients were eligible to receive open-label Netakimab for a total treatment duration of up to three years.[19]

The primary endpoint of the ASTERA trial was the proportion of patients achieving at least a 40% improvement in the Assessment of SpondyloArthritis international Society response criteria (ASAS40) at Week 16.[19] Netakimab demonstrated clear superiority over placebo, with 40.4% of patients in the active treatment arm achieving an ASAS40 response, compared to only 2.6% in the placebo arm (

p<0.0001).[19]

A particularly notable finding from the ASTERA trial was the rapid onset of clinical effect. Patients treated with Netakimab experienced a subsidence of spinal pain and a decrease in laboratory markers of inflammation, such as C-reactive protein (CRP), within the first week after the initial injection.[19] This rapid relief is a highly valuable attribute in a condition characterized by significant pain and stiffness. The long-term extension of the study confirmed the durability of this effect, with most patients maintaining a sustained decline in disease activity (measured by ASDAS-CRP and BASDAI) over three years of continuous therapy, with no evidence of significant loss of response.[20] Furthermore, a sub-analysis of the ASTERA data confirmed that Netakimab was equally effective in patients who were naïve to biologic therapy and in a difficult-to-treat population of patients who had an inadequate response to prior TNF inhibitor therapy, demonstrating its utility across different lines of treatment.[26]

Indication (Trial Name)	Efficacy Endpoint	Netakimab (%)	Placebo (%)	p-value
Plaque Psoriasis (PLANETA)	PASI 75 @ Wk 12 (Q4W arm)	83.3	0	<0.0001 16
Psoriatic Arthritis (PATERA)	ACR20 @ Wk 24	82.5	9.3	<0.0001 17
Ankylosing Spondylitis (ASTERA)	ASAS40 @ Wk 16	40.4	2.6	<0.0001 19

Comprehensive Safety, Tolerability, and Immunogenicity Profile

Consolidated Adverse Event (AE) Profile

Across the pivotal PLANETA, PATERA, and ASTERA clinical trial programs, Netakimab has consistently demonstrated a favorable safety profile and was generally well-tolerated by patients.[7] During the double-blind, placebo-controlled periods of these studies, the overall incidence of adverse events in the Netakimab arms was comparable to that observed in the placebo arms.[8] The majority of reported AEs were mild to moderate in severity.[17]

The types of AEs observed are consistent with the known class effects of IL-17 inhibitors, reflecting the mechanism of action of this therapeutic class.[8] The most frequently reported AEs across the clinical program include:

• Laboratory Abnormalities: Changes in laboratory parameters were among the most common findings. These included neutropenia (reported in 7.0% of AS patients in ASTERA), lymphopenia, and elevations in liver enzymes, specifically Alanine Aminotransferase (ALT) (reported in 6.1% of AS patients).[17] Other reported laboratory changes included hypercholesterolemia, hyperglycemia, and hyperbilirubinemia.[17]
• Infections: An increased risk of infection is a known consideration for IL-17 inhibitors due to the role of IL-17 in mucosal and epithelial host defense. The most commonly reported infections were non-serious upper respiratory tract infections (e.g., nasopharyngitis).[10]
• Other Common AEs: Other frequently observed AEs included injection site reactions (such as redness, swelling, or pain), headache, and fatigue.[10]

Serious adverse events (SAEs) were uncommon. In the PATERA study for psoriatic arthritis, severe treatment-related AEs were reported in only 1.03% of patients receiving Netakimab, a rate lower than that seen in the placebo group (2.06%).[17] No treatment-related SAEs were reported in that trial's 24-week blinded period.[17] Long-term data from the ASTERA study extension showed that over three years, 36.7% of patients experienced AEs, primarily laboratory abnormalities and infectious complications, which were mostly mild to moderate.[20]

Immunogenicity

The potential for a biologic drug to elicit an immune response in the patient, leading to the formation of anti-drug antibodies (ADAs), is a critical aspect of its long-term safety and efficacy profile. ADAs can neutralize the drug's activity or accelerate its clearance, leading to a loss of clinical response over time.

Netakimab was specifically designed with a "smart humanization" process to minimize its immunogenic potential.[4] Clinical data have largely borne out the success of this approach. Multiple studies have reported that Netakimab demonstrates low immunogenicity.[7] In the 24-week blinded period of the PATERA study, no ADAs were detected in any patient treated with Netakimab.[17] This lack of an early immune response is a strong positive indicator for long-term drug survival. More extended follow-up from the 3-year PATERA study provided a longer-term perspective, noting that ADAs were eventually detected in 9.3% of patients. The formation of these antibodies typically occurred toward the end of the first year or the beginning of the second year of therapy.[25] While the specific clinical impact of these late-forming ADAs was not detailed, the overall clinical efficacy of Netakimab was reported to be well-maintained over the three-year period, suggesting that the detected ADAs were not, in the majority of cases, clinically significant.[25] This low rate of ADA formation is a potentially significant advantage, as it may predict better long-term durability of response compared to other biologics with higher rates of immunogenicity.

Contraindications and Precautions

While a full, regulator-approved prescribing information document for the US or EU is not available, the known risks of the IL-17 inhibitor class and information from clinical trial exclusion criteria provide a clear picture of the necessary precautions.

• Hypersensitivity: Netakimab is contraindicated in patients with a known history of serious hypersensitivity reaction to the active substance or any of its excipients.[10]
• Active Infections: Treatment with Netakimab should not be initiated in patients with any clinically important active infection. As IL-17 is integral to the immune defense against certain pathogens, particularly fungal and bacterial, inhibiting its function can increase the risk of serious infections.[10] If a patient develops a serious infection during treatment, Netakimab should be discontinued until the infection resolves.
• Tuberculosis (TB): Prior to initiating therapy, all patients should be evaluated for latent TB infection. Patients with latent TB should be treated with standard anti-tuberculosis therapy before starting Netakimab.[10]
• Inflammatory Bowel Disease (IBD): Caution is advised when prescribing Netakimab to patients with IBD (Crohn's disease or ulcerative colitis). Exacerbations of IBD have been observed with IL-17 inhibitors.[30]
• Immunizations: The use of live vaccines should be avoided in patients undergoing treatment with Netakimab, as the immunosuppressive effect of the drug may increase the risk of infection from the vaccine and reduce its efficacy.[10]
• Concomitant Immunosuppressants: Co-administration of Netakimab with other potent immunosuppressive agents should be avoided due to the potential for an additive effect on the immune system, which could further increase the risk of infection.[10]

Adverse Event	Plaque Psoriasis (PLANETA)	Psoriatic Arthritis (PATERA)	Ankylosing Spondylitis (ASTERA)	Notes / Class Comparison
Neutropenia	Not specified	Reported (≥3%) 17	7.0% 19	A known class effect of IL-17A inhibition. Requires monitoring.
ALT Increased	Not specified	Reported (≥3%) 17	6.1% 19	Common with IL-17 inhibitors. Requires liver function monitoring.
Upper Respiratory Tract Infection	Not specified	Reported (≥3%) 17	Not specified	Most common AE for the IL-17 inhibitor class. Generally mild.
Lymphopenia	Not specified	Reported (≥3%) 17	Not specified	A known class effect. Requires monitoring of complete blood count.
Immunogenicity (ADA formation)	Low 16	0% at 24 weeks 17; 9.3% at 3 years 25	Not specified	Low rate is a potential long-term advantage.

Pharmacokinetics (PK)

The pharmacokinetic profile of a monoclonal antibody—describing its absorption, distribution, metabolism, and excretion (ADME)—is fundamental to understanding its dosing regimen, efficacy, and safety.

Summary of PK Studies

The formal investigation of Netakimab's pharmacokinetics began with a dedicated Phase 1 clinical trial (NCT02380287).[14] This study, conducted in 37 healthy male volunteers, was designed to assess the safety and PK profile of single subcutaneous injections of Netakimab at various doses. The primary goal was to establish a safe and effective dose range to carry forward into Phase 2 patient trials.[14] This trial commenced in March 2015 and was completed by October 2015.[14]

Following the initial healthy volunteer study, pharmacokinetic and immunogenicity assessments were integrated as secondary objectives within the broader Phase 2 and Phase 3 clinical trials conducted in patients with ankylosing spondylitis (NCT02763111), plaque psoriasis (NCT02762994), and the pivotal Phase 3 programs.[3] These in-patient studies provide PK data that are more representative of the target populations, where disease states and concomitant medications can influence drug disposition. However, specific quantitative PK parameters such as terminal half-life (

t1/2​), maximum concentration (Cmax​), area under the curve (AUC), volume of distribution, and bioavailability have not been detailed in the publicly available literature provided. This represents a notable gap in the publicly accessible data, as these parameters are crucial for detailed modeling, cross-drug comparisons, and a full understanding of the drug's behavior in the body.

General Principles of Monoclonal Antibody PK

As a large protein therapeutic—a humanized IgG1 monoclonal antibody with a molecular weight of approximately 146 kDa—Netakimab is expected to follow the general pharmacokinetic principles characteristic of its class.[34]

• Absorption: Due to its large size and protein nature, Netakimab would be degraded in the gastrointestinal tract and has negligible oral bioavailability. Therefore, it is administered via subcutaneous injection, from where it is slowly absorbed into circulation, primarily via the lymphatic system.[34]
• Distribution: Like other mAbs, Netakimab has a relatively small volume of distribution. Its large size and hydrophilic nature restrict its movement primarily to the vascular (bloodstream) and interstitial (fluid surrounding cells) compartments. It does not readily cross cellular membranes or the blood-brain barrier.[34]
• Metabolism and Excretion: Netakimab is not metabolized by the hepatic cytochrome P450 (CYP450) enzyme system, which is the primary pathway for small-molecule drug metabolism.[34] This characteristic means that Netakimab is unlikely to be the subject of or cause direct, metabolism-based drug-drug interactions with medications that are substrates, inhibitors, or inducers of CYP enzymes.[37] Instead, it is cleared from the body through intracellular catabolism. The antibody is taken up by cells via pinocytosis and broken down into smaller peptides and amino acids, which are then recycled by the body.[34] This process is not saturable at therapeutic doses and is the same pathway used for the clearance of endogenous immunoglobulins, typically resulting in a long elimination half-life measured in weeks.[34]

Global Regulatory Status and Future Development

Current Market Approvals

Netakimab has successfully navigated the regulatory process in Russia and Belarus, securing approval for its three primary indications.

• Russian Federation: The first regulatory approval for Netakimab was granted by the Ministry of Health of the Russian Federation on April 3, 2019, for the treatment of psoriatic arthritis.[3] This was followed by approvals for moderate-to-severe plaque psoriasis and active ankylosing spondylitis.[4]
• Republic of Belarus: Netakimab is also approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis in Belarus.[23]

International Development Pipeline

Biocad is pursuing a strategic international expansion for Netakimab, with a clear focus on markets in Asia and a stated ambition to enter the European market.

• China: A significant part of the global strategy involves the Chinese market, pursued through a partnership with Shanghai Pharmaceuticals Holding (SPH-BIOCAD).[1] Several Phase 3 clinical trials are active and recruiting in China to support local registration:
• A trial in Chinese adult patients with moderate-to-severe plaque psoriasis (NCT07008547).[3]
• A trial in Chinese adult patients with active ankylosing spondylitis (CTR20222555).[3]
• Pediatric Development: Recognizing the need for effective biologics in younger populations, Biocad has initiated a Phase 3 trial known as PLANETA-KIDS (NCT06640517). This study is designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of Netakimab in children and adolescents (ages 6 to under 18) with moderate-to-severe plaque psoriasis.[3]
• European Union (EU) and United States (US): Biocad has publicly stated its intention to pursue marketing authorization in the EU and has planned to launch international clinical trials to support this goal.[39] However, as of the latest available information, there is no active Marketing Authorisation Application (MAA) under review by the European Medicines Agency (EMA).[40] The path to approval in the US is less clear, with no publicly disclosed plans or active applications with the Food and Drug Administration (FDA).[6] Entry into these highly competitive and regulated Western markets represents a significant future challenge. The existing pivotal trials were placebo-controlled, and regulators in the US and EU may require additional data, potentially including head-to-head trials against an established active comparator, to grant approval.

Exploratory Indications

The therapeutic potential of Netakimab has been explored beyond its core indications. A Phase 2 clinical trial was initiated in Russia to investigate its efficacy in Primary Biliary Cholangitis, an autoimmune liver disease.[1] However, this trial is listed as inactive or terminated, suggesting that development in this indication is not currently being pursued.[2]

Trial Identifier	Trial Name/Acronym	Indication	Phase	Status	Location(s)
NCT02380287	-	Healthy Volunteers (PK/Safety)	1	Completed	Russia 6
NCT02762994	-	Plaque Psoriasis	2	Completed	Russia 7
NCT02763111	-	Ankylosing Spondylitis	2	Completed	Russia 14
NCT03390101	PLANETA	Moderate-to-Severe Plaque Psoriasis	3	Completed	Russia, Belarus 3
NCT03598751	PATERA	Psoriatic Arthritis	3	Completed	Russia, Belarus 3
NCT03447704	ASTERA	Ankylosing Spondylitis	3	Completed	Russia, Belarus 3
NCT06640517	PLANETA-KIDS	Pediatric Plaque Psoriasis	3	Active, not recruiting	Russia 3
NCT07008547	-	Moderate-to-Severe Plaque Psoriasis	3	Active, not recruiting	China 3
CTR20222555	-	Ankylosing Spondylitis	3	Active, not recruiting	China 3
-	-	Primary Biliary Cholangitis	2	Inactive/Terminated	Russia 1

Strategic Analysis and Concluding Remarks

Competitive Positioning in the IL-17 Inhibitor Class

Netakimab enters a well-established therapeutic class dominated by global pharmaceutical players. Its competitive positioning must be assessed based on its comparative efficacy, safety, and potential points of differentiation.

Network meta-analyses, which allow for indirect comparisons of drugs across different trials, provide valuable context. One such analysis focusing on psoriasis found that Netakimab's effectiveness (measured by PASI 75 at 12 weeks) was statistically comparable to that of other direct IL-17A inhibitors like secukinumab and ixekizumab, and superior to older biologics such as adalimumab and etanercept.[46] In the context of ankylosing spondylitis, another network meta-analysis ranked Netakimab 120 mg as the most effective intervention for achieving both ASAS20 and ASAS40 responses when compared to other IL-17 and JAK inhibitors, although this finding may be limited by the number of Netakimab trials included.[47]

From a safety perspective, Netakimab's profile aligns closely with its class. The meta-analysis found no significant differences in safety between Netakimab and other IL-17 inhibitors, suggesting it does not carry an undue risk but also does not offer a clear safety advantage based on currently available data.[46]

Therefore, Netakimab's key differentiators are more nuanced. The first is its unique molecular structure derived from llama VHH domains. The direct clinical consequence of this design appears to be a low immunogenicity profile. In a field where long-term treatment is necessary and secondary loss of efficacy due to anti-drug antibodies is a significant clinical concern, a lower rate of immunogenicity could translate into superior drug survival and more durable patient outcomes over many years of therapy. The second potential differentiator is its reported dual binding to both IL-17A and IL-17F. While the clinical impact of its IL-17F inhibition has not been explicitly quantified in its pivotal trials, the success of bimekizumab, a dedicated dual IL-17A/F inhibitor, suggests that this mechanism may offer enhanced efficacy, particularly for complete skin clearance in psoriasis. If further data substantiates a clinically meaningful effect from IL-17F blockade, Netakimab could be positioned as a more advanced agent than first-generation IL-17A-only inhibitors.

Unmet Needs and Future Outlook

Netakimab effectively addresses the needs of patients with moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, including those who are biologic-naïve and those who have failed previous therapies like TNF inhibitors. Its rapid onset of action is a particularly valuable feature for patients suffering from the debilitating pain and inflammation associated with these conditions.

The future global outlook for Netakimab is contingent on Biocad's strategic decisions. The "East-first" commercialization strategy—securing approval in Russia and prioritizing expansion into China—allows the company to generate revenue and valuable real-world evidence in key markets before undertaking the costly and complex process of seeking approval in the West. The ongoing expansion into pediatric psoriasis is a standard and important lifecycle management strategy that addresses a clear unmet need for safe and effective long-term treatments for children.[48]

However, the path to the US and EU markets presents high barriers. The immunology market is crowded, and payers and regulators will likely require compelling evidence of value, which may necessitate head-to-head clinical trials demonstrating non-inferiority or superiority against an established active comparator. The success of Netakimab's journey will serve as a significant test case for the ability of a major biologic therapy developed outside the traditional Western pharmaceutical industry to achieve global market penetration, potentially signaling a shift in the global biopharmaceutical landscape.

Concluding Expert Assessment

Netakimab is a scientifically innovative and clinically potent IL-17 inhibitor. The robust and consistent efficacy demonstrated across its pivotal trial program, combined with a manageable safety profile and low immunogenicity, establishes it as a valuable therapeutic option for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its unique molecular engineering, leveraging a llama-derived VHH domain, appears to confer a tangible clinical advantage in minimizing immunogenicity, which may be its most important long-term differentiator.

While Netakimab has established a solid foothold in its home market and is poised for expansion into China, its ultimate position as a global therapy is yet to be determined. Its future will be defined by the outcomes of its ongoing international and pediatric trials and Biocad's ability to navigate the complex regulatory and competitive environments of Western markets. Nevertheless, Netakimab represents a significant achievement in biopharmaceutical development and stands as a noteworthy asset to monitor as it continues its global journey.

Works cited

1. Netakimab - Biocad - AdisInsight - Springer, accessed September 16, 2025, https://adisinsight.springer.com/drugs/800042162
2. Netakimab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 16, 2025, https://go.drugbank.com/drugs/DB18870
3. Netakimab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 16, 2025, https://synapse.patsnap.com/drug/b199866b0ff94fb1a2cdc537b5f87a78
4. BIOCAD — innovative biotechnology company — Netakimab, accessed September 16, 2025, https://eng.biocad.ru/products/netakimab
5. Anti-IL17 netakimab registered in Russia - The Antibody Society, accessed September 16, 2025, https://www.antibodysociety.org/antibody-therapeutic/anti-il17-netakimab-registered-in-russia/
6. Netakimab Approved Naked monospecific - The Antibody Society, accessed September 16, 2025, https://db.antibodysociety.org/db0/29/
7. (PDF) Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial - ResearchGate, accessed September 16, 2025, https://www.researchgate.net/publication/352023248_Efficacy_and_Safety_of_Netakimab_A_Novel_Anti-IL-17_Monoclonal_Antibody_in_Patients_with_Moderate_to_Severe_Plaque_Psoriasis_Results_of_A_54-Week_Randomized_Double-Blind_Placebo-Controlled_PLANETA_Cli
8. The efficacy and safety of netakimab in patients with psoriatic arthritis: results from the Phase III clinical study PATERA, accessed September 16, 2025, https://rsp.mediar-press.net/rsp/article/download/2949/2023
9. Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis - Frontiers, accessed September 16, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.715510/full
10. What is Netakimab used for? - Patsnap Synapse, accessed September 16, 2025, https://synapse.patsnap.com/article/what-is-netakimab-used-for
11. What is the mechanism of Netakimab? - Patsnap Synapse, accessed September 16, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-netakimab
12. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications - Frontiers, accessed September 16, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.03096/full
13. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in ..., accessed September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10299014/
14. Netakimab (BCD-85) for Ankylosing Spondylitis, accessed September 16, 2025, https://ankylosingspondylitisnews.com/netakimab-bcd-085/
15. Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis - ResearchGate, accessed September 16, 2025, https://www.researchgate.net/publication/351665683_Out_of_the_shadow_of_interleukin-17A_the_role_of_interleukin-17F_and_other_interleukin-17_family_cytokines_in_spondyloarthritis
16. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial - PubMed, accessed September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/34060012/
17. OP0226 NETAKIMAB DECREASES DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED DOUBLE-BLIND PHASE 3 CLINICAL TRIAL (PATERA), accessed September 16, 2025, https://ard.bmj.com/content/79/Suppl_1/141
18. Arthritis, Psoriatic Completed Phase 3 Trials for Netakimab (DB18870) | DrugBank Online, accessed September 16, 2025, https://go.drugbank.com/indications/DBCOND0000314/clinical_trials/DB18870?phase=3&status=completed
19. Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody ..., accessed September 16, 2025, https://rsp.mediar-press.net/rsp/article/view/2925?locale=en_US
20. Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA | Mazurov | Modern Rheumatology Journal, accessed September 16, 2025, https://mrj.ima-press.net/mrj/article/view/1529?locale=en_US
21. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis - Vestnik dermatologii i venerologii, accessed September 16, 2025, https://vestnikdv.ru/jour/article/view/480
22. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis - Semantic Scholar, accessed September 16, 2025, https://www.semanticscholar.org/paper/Netakimab-%E2%80%94-new-IL-17%D0%B0-inhibitor%3A-12-week-results-Kubanov-%D0%9A%D1%83%D0%B1%D0%B0%D0%BD%D0%BE%D0%B2/180264fa16b38b2986e3c1e34357472d3ab6435c
23. POS1043 NETAKIMAB REDUCES PSORIATIC ARTHRITIS ACTIVITY IN PATIENTS WITH OR WITHOUT AXIAL DISEASE: SUBANALYSIS OF THE PATERA STUDY, accessed September 16, 2025, https://ard.bmj.com/content/80/Suppl_1/796
24. Netakimab demonstrates superiority to placebo in second-line psoriatic arthritis - | BioWorld, accessed September 16, 2025, https://www.bioworld.com/articles/678187-netakimab-demonstrates-superiority-to-placebo-in-second-line-psoriatic-arthritis
25. Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study | Korotaeva | Modern Rheumatology Journal, accessed September 16, 2025, https://mrj.ima-press.net/mrj/article/view/1618?locale=en_US
26. POS0928 NETAKIMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-EXPERIENCED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL | Request PDF - ResearchGate, accessed September 16, 2025, https://www.researchgate.net/publication/351862771_POS0928_NETAKIMAB_EFFICACY_IN_ANTI-TNF-NAIVE_AND_ANTI-TNF-EXPERIENCED_PATIENTS_WITH_ACTIVE_ANKYLOSING_SPONDYLITIS_RESULTS_OF_SUBANALYSIS_OF_PHASE_3_ASTERA_TRIAL
27. POS0928 NETAKIMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-EXPERIENCED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL | Annals of the Rheumatic Diseases, accessed September 16, 2025, https://ard.bmj.com/content/80/Suppl_1/726.2
28. What are the side effects of Netakimab? - Patsnap Synapse, accessed September 16, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-netakimab
29. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults - Clinical and Experimental Rheumatology, accessed September 16, 2025, https://www.clinexprheumatol.org/article.asp?a=13535
30. Secukinumab (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed September 16, 2025, https://www.mayoclinic.org/drugs-supplements/secukinumab-intravenous-route-subcutaneous-route/description/drg-20137344
31. Secukinumab Interactions Checker - Drugs.com, accessed September 16, 2025, https://www.drugs.com/drug-interactions/secukinumab.html
32. Cosentyx Interactions Checker - Drugs.com, accessed September 16, 2025, https://www.drugs.com/drug-interactions/secukinumab,cosentyx.html
33. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults - PubMed, accessed September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/31025924/
34. Pharmacokinetic Characteristics of Monoclonal Antibody Drugs - Creative Proteomics, accessed September 16, 2025, https://www.creative-proteomics.com/pronalyse/pharmacokinetic-characteristics-of-monoclonal-antibody-drugs.html
35. Pharmacokinetics of Monoclonal Antibodies - PMC - PubMed Central, accessed September 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5613179/
36. Netakimab | Anti-IL-17 Antibody - MedchemExpress.com, accessed September 16, 2025, https://www.medchemexpress.com/netakimab.html
37. Drug interactions of monoclonal antibodies-clinical perspective - Journal of Immunological Sciences, accessed September 16, 2025, https://www.immunologyresearchjournal.com/articles/drug-interactions-of-monoclonal-antibodiesclinical-perspective.html
38. Efleira (netakimab) / Biocad - LARVOL DELTA, accessed September 16, 2025, https://delta.larvol.com/Products/?ProductId=eb22dff1-839c-4dfd-9dae-a355ded0b0a5
39. Netakimab | BIOCAD - CPHI Online, accessed September 16, 2025, https://www.cphi-online.com/product/netakimab/
40. Cosentyx | European Medicines Agency (EMA), accessed September 16, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
41. European Medicines Agency Archives - Page 2 of 5 - The Antibody Society, accessed September 16, 2025, https://www.antibodysociety.org/european-medicines-agency/page/2/
42. European Medicines Agency Archives - The Antibody Society, accessed September 16, 2025, https://www.antibodysociety.org/european-medicines-agency/
43. 9 New Treatments for Psoriatic Arthritis Currently in Clinical Trials - GoodRx, accessed September 16, 2025, https://www.goodrx.com/conditions/psoriatic-arthritis/new-drugs-for-psoriatic-arthritis
44. Netakimab Completed Phase 2 Trials for Psoriasis Treatment | DrugBank Online, accessed September 16, 2025, https://go.drugbank.com/drugs/DB18870/clinical_trials?conditions=DBCOND0013339&phase=2&purpose=treatment&status=completed
45. Ankylosing Spondylitis (AS) Completed Phase 2 Trials for Netakimab (DB18870), accessed September 16, 2025, https://go.drugbank.com/indications/DBCOND0046486/clinical_trials/DB18870?phase=2&status=completed
46. 1 University of Oxford, BIOCAD, St. Petersburg, Russia; 2BIOCAD, St ..., accessed September 16, 2025, https://www.ispor.org/docs/default-source/euro2019/biocadpostersystematic-review-pdf.pdf?sfvrsn=d838f6ad_0
47. Efficacy and Safety of Interleukin-17 and Janus Kinase Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis - PubMed, accessed September 16, 2025, https://pubmed.ncbi.nlm.nih.gov/40010328/
48. Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives - MDPI, accessed September 16, 2025, https://www.mdpi.com/1422-0067/23/19/11128